Spitfire List Web site and blog of anti-fascist researcher and radio personality Dave Emory.

For The Record  

FTR #912 Food for Thought

Dave Emory’s entire life­time of work is avail­able on a flash drive that can be obtained here. The new drive is a 32-gigabyte drive that is current as of the programs and articles posted by early winter of 2016. The new drive (available for a tax-deductible contribution of $65.00 or more.)  (The previous flash drive was current through the end of May of 2012.)

WFMU-FM is podcasting For The Record–You can subscribe to the podcast HERE.

You can subscribe to e-mail alerts from Spitfirelist.com HERE

You can subscribe to RSS feed from Spitfirelist.com HERE.

You can subscribe to the comments made on programs and posts–an excellent source of information in, and of, itself HERE.

This program was recorded in one, 60-minute segment.

The corporate logo of I.G. Farben.

The corporate logo of I.G. Farben.

Martin Bormann (right) with Himmler

Martin Bormann (right) with Himmler

Introduction: This program is speculative in nature, evaluating the possibility that companies descended from the I.G. Farben German chemical cartel may absorb Monsanto, the firm noted for its development of genetically modified organisms.

Specifically, Bayer and BASF figure in the reported maneuvering for Monsanto.

Against the background of the remarkable Bormann capital network’s effective control of the firms that descended from I.G. Farben, we ruminate about the possibility of genetically engineered binary pathogens being included in the food supply available to much of the world’s population.

Available information highlights possible Underground Reich maneuvering to gain control of firms marketing foodstuffs to middle, lower middle and working class people. This speculation, in turn, is set against the background of information strongly suggesting that AIDS was deliberately developed.

For more than three decades, Mr. Emory has presented programs indicating that AIDS is a man-made disease. Supplementing that body of work, this program sets forth circumstantial evidence indicating that AIDS may have been created on a foundation of research done by the Nazis in concentration camps during the Second World War. Under a program named Project Paperclip, Nazi scientists—many of them war criminals—were recruited to do research for the U.S. national security establishment.

Jorge Paulo Lemann

Jorge Paulo Lemann

Recent medical research indicates the existence of a genetic trait that affords immunity to both AIDS and the infections that have come to be known as “plague.” (Originally thought to be an outbreak of bubonic plague–a bacteriological disease–recent research has shifted focus to a viral disease more akin to Ebola.)

This gene—the CCR5 delta-32 mutation—is only carried by the white race and [according to some sources] only by people of Northern European extraction. Did the Nazis note [in their experiments] that some people appeared to be immune to infection with plague? Were tissue samples taken and preserved for further study? Was this in any way connected to the eventual evolution of the CCR5-delta 32 gene as a hereditary protection against infection by HIV?

In June of 2009, it emerged that CCR5 delta-32 was used in transplant therapy administered by a German doctor to an HIV-positive leukemia patient. It appears that the patient was cured of HIV! The German doctor deliberately selected a CCR5 delta-32 positive donor for the stem cells used for the transplant.

Obviously, we are wondering about the possibility of the Underground Reich using foodstuffs to vector humanity with genetically engineered pathogens that will realize Hitler’s dream of an “Aryan” world.

Program Highlights Include:

  • Becker GMBH’s genesis with the SS and capital stolen from Jews during the Holocaust.
  • Becker GMBH’s absorption into ConAgra foods.
  • The growing participation by Jorge Paulo Lemann in foodstuffs and beverages consumed by middle, lower-middle and working class people.
  • Speculation about Lemann’s participation in the Bormann capital network.
  • BASF’s partnering with Monsanto and the possibility that the firm may acquire any subsidiary firms that Bayer may have to spin off to acquire Monsanto.

1a. Bayer may be poised to buy Monsanto.

“Bayer Takeover of Mon­santo Would Cre­ate a Global Giant” [AP]; The Los Angeles Times; 5/19/2016.

Bayer’s poten­tial acqui­si­tion of Mon­santo Co. would cre­ate a giant seed and farm chem­i­cal com­pany with a strong foot­print in the U.S., Europe and Asia, com­bin­ing two busi­nesses with com­ple­men­tary geo­graph­i­cal focus.

But Bayer might have to shed part of its busi­ness because of antitrust con­cerns. [Consider that in light of the Bloomberg story about BASF–D.E.] And the price tag on any deal would be huge: Monsanto’s mar­ket value is around $42 billion.

Germany-based Bayer said Thurs­day in a short state­ment that its exec­u­tives had met recently with their Mon­santo coun­ter­parts “to pri­vately dis­cuss a nego­ti­ated acqui­si­tion” of the spe­cial­ist in genet­i­cally mod­i­fied crop seeds.

The news of a poten­tially costly deal sent Bayer shares tum­bling 8.2%. Mon­santo shares climbed 3.5%.

Both com­pa­nies are famil­iar brands on farms around the globe. Bayer, whose farm busi­ness pro­duces seeds as well as com­pounds to kill weeds, bugs and fun­gus, said the pro­posed acqui­si­tion would help it “cre­ate a lead­ing inte­grated agri­cul­ture business.”

Mon­santo, based in St. Louis, said it was review­ing Bayer’s pro­posal. Nei­ther com­pany gave other details.

The pos­si­ble deal had been rumored for a week, but these were the first com­ments from either company.

“A com­bi­na­tion of both com­pa­nies would cre­ate $67 bil­lion of annual sales and the world’s largest seed and crop-chemical com­pany,” ana­lyst Ulrich Huwald at War­burg Research wrote in a research note to investors. “How­ever, the ques­tion is if Mon­santo would be inter­ested in a deal.”

Huwald said that “the busi­nesses are geo­graph­i­cally com­ple­men­tary, with Mon­santo hav­ing a strong pres­ence in North Amer­ica and Bayer in Europe and Asia.”

A com­bi­na­tion of the two would have 28% of the global mar­ket for pes­ti­cides and a strong pres­ence in the U.S. corn and soy­bean seed business.

Huwald said that the two com­pa­nies do over­lap in their veg­etable and cot­ton seed busi­ness, which could require divest­ments due to antitrust issues. Bayer might also have to sell parts of its weed killer business.

Antitrust reg­u­la­tors scru­ti­nize merg­ers and takeovers and have the author­ity to block them if they hin­der free-market com­pe­ti­tion. If com­pa­nies get too much con­trol over a mar­ket, they can charge higher prices and have fewer incen­tives to innovate.

News of the talks fol­lows a wave of con­sol­i­da­tion in the chem­i­cal indus­try: DuPont and Dow Chem­i­cal agreed to com­bine last year, and Chem­China agreed to buy Syn­genta of Switzer­land in March after Monsanto’s own bid for its Basel-based rival failed. . . . .

1b. We note that BASF, like Bayer, one of the successor companies to I.G. Farben, has partnered with Monsanto in many of their GMO projects. “ . . . . More­over, a Bayer-Monsanto tie-up may put BASF’s col­lab­o­ra­tion with the Amer­i­cans at risk. BASF and Mon­santo work together on research and devel­op­ment in plant biotech­nol­ogy, giv­ing a strong rea­son, per­haps, to spoil Bayer’s plans. . . . “

“BASF Best Leav­ing Mon­santo Seeds for the Birds” by Olaf Storbeck; Reuters; 5/19/2016.

There is one thing the share­hold­ers of the chem­i­cal com­pany BASF should fear more than con­sol­i­da­tion between its Ger­man rival Bayer and the Amer­i­can seed maker Mon­santo: their own board wad­ing in with a counterbid.

Bayer’s bid for Mon­santo puts BASF’s chief exec­u­tive, Kurt Bock, on the spot. With agri­cul­tural rev­enue of 5.8 bil­lion euros ($6.5 bil­lion), BASF is one of the world’s big play­ers in an indus­try where every­one seems to be enthu­si­as­ti­cally cou­pling. Think of Dow Chemical’s merger with DuPont, and Syngenta’s planned takeover by Chem­China. Only BASF would be left on the shelf.

More­over, a Bayer-Monsanto tie-up may put BASF’s col­lab­o­ra­tion with the Amer­i­cans at risk. BASF and Mon­santo work together on research and devel­op­ment in plant biotech­nol­ogy, giv­ing a strong rea­son, per­haps, to spoil Bayer’s plans. . . .

1c. IF Bayer does purchase Monsanto and is forced to divest itself of some subsidiary firms due to anti-trust considerations, BASF may well pick up those firms that are “spun off,” thus giving the Underground Reich effective control of the GMO food business.

“. . . . In the lead up to Bayer AG’s unso­licited takeover pro­posal for Mon­santo Co on Thurs­day, Chief Exec­u­tive Offi­cer Kurt Bock has talked up thrift, balk­ing at the price tags placed on assets. Rather than bet­ting the farm on a big deal and chal­leng­ing arch agro­chem­i­cals rival Bayer for Mon­santo, Bock appears con­tent to stay out of the fray, ready to selec­tively buy up any busi­nesses that may come to the mar­ket in the dust of mega deals. . . .”

“BASF Is Sleep­ing Giant on Deals as Bayer Moves on Monsanto” by Sheenagh Matthews and Andrew Marc Noel; Bloomberg; 5/19/2016.

* Ger­man chem­i­cals maker fears over­pay­ing, los­ing inte­gra­tion
* CEO Kurt Bock may buy agro­chem­i­cals assets dis­carded on deals

With an aver­sion to over­pay­ing and con­vic­tion that a con­glom­er­ate approach is best, Germany’s BASF SE has so far sat out the biggest-ever con­sol­i­da­tion wave in the global crop chem­i­cals and seeds industry.

In the lead up to Bayer AG’s unso­licited takeover pro­posal for Mon­santo Co on Thurs­day, Chief Exec­u­tive Offi­cer Kurt Bock has talked up thrift, balk­ing at the price tags placed on assets. Rather than bet­ting the farm on a big deal and chal­leng­ing arch agro­chem­i­cals rival Bayer for Mon­santo, Bock appears con­tent to stay out of the fray, ready to selec­tively buy up any busi­nesses that may come to the mar­ket in the dust of mega deals. . . . .

2. The I.G. Farben company, a core element of the Third Reich, was central to Reichsleiter Martin Bormann’s plans to secret Germany’s wealth abroad. Note, also, I.G. Farben’s dominance of the European chemical industry, and the opinion of Dr. von Schnitzler that technical dependence on I.G. facilities would continue after the war. (To learn more about I.G. Farben, see—among other programs–FTR#’s 305411506552. Serious students should also read Treason’s Peace and The Devil’s Chemists, available for download.)

Martin Bormann: Nazi in Exile; Paul Manning; Copyright 1981 [HC]; Lyle Stuart Inc.; ISBN 0-8184-0309-8; p. 28.

 . . . I.G. Farben was a formidable ally for Reichsleiter Bormann in his plans for the postwar economic rebirth of Germany. In a telephone conversation with Dr. von Schnitzler, Bormann asked what would the loss of factories in France and the other occupied countries mean to German industry in general and to I.G. in particular. Dr. von Schnitzler said he believed the technical dependence of these countries on I.G. would be so great that despite German defeat I.G., in one way or another, could regain its position of control of the European chemical business. ‘They will need the constant technical help of I.G.’s scientific laboratories as they do not own appropriate installations within themselves.’ . . . (Ibid.; p. 28.)

3. Bormann and Schmitz then discussed I.G.’s prospects for the postwar period. The cozy relationship with powerful elements within the power elites of the Western allies was foreseen by Schmitz as boding well for the company’s future. Schmitz’s predictions were relatively accurate. Neither Schmitz nor any of the I.G. Farben executives were severely punished and the firm’s three successor firms carried on effectively in the postwar period.

Martin Bormann: Nazi in Exile; Paul Manning; Copyright 1981 [HC]; Lyle Stuart Inc.; ISBN 0-8184-0309-8; p. 158.

. . . .The Reichsleiter asked Schmitz his views of the future. Schmitz replied, ‘The occupation armies will be understanding in the West, but certainly not in the East. I have instructed all Farben administrators and technicians to come to the West, where they can be of use in resuming our operations once the disturbances of 1945 come to a halt.’ Schmitz added that, while general bomb damage to the I.G. plants was about 25 percent of capacity, some were untouched. He mentioned speaking with Field Marshal Model, who was commanding the defenses of the Ruhr. ‘Model had planned to turn our Bayer-Leberkusen pharmaceutical factory into an artillery base, but he agreed to make it an open, undefended factory. Hopefully, we will get it back untouched.’ ‘What about your board of directors and the essential executives? If they are held by the occupation authorities, can I.G. continue?’ Bormann asked. ‘We can continue. We have an operational plan for such a contingency, which everyone understands. However, I don’t believe our board members will be detained too long. Nor will I. But we must go through a procedure of investigation before release, so I have been told by our N.W. 7 people who have excellent contacts in Washington.’ . . .

4. The broadcast details the profound relationship between I.G. Farben and the government of the Third Reich. Of particular utility to the Bormann flight capital program was I.G. Farben’s elaborate infrastructure in foreign countries. Note that, as is seen here, I.G. Farben was inextricably linked with both the government of the Third Reich and with the Nazi party itself. Of particular significance is the N.W.7 office and its control by Martin Bormann.

Martin Bormann: Nazi in Exile; Paul Manning; Copyright 1981 [HC]; Lyle Stuart Inc.; ISBN 0-8184-0309-8; p. 54.

 . . . This, too, reported to Martin Bormann.I.G. Farben’s N.W.7 office in Berlin compiled military and economic data on all countries for the Wehrmacht. This department was staffed with men of recognized ability in all branches of business and science. It was under the direction of Dr. Max Ilgner, nephew of Hermann Schmitz, I.G.’s president, who was known throughout the industrial world as ‘the master of financial camouflage.’ [Emphasis added.] Farben had offices and representatives in 93 countries, and no social gathering of businessmen was too small to be covered by an N.W.7 representative, whose reports on market conditions, factory installations, raw-material supplies, and research were transmitted immediately to Berlin and Dr. Ilgner. In the United States, N.W.7 operated through the firm of Chemnyco, Inc., an American-formed subsidiary. Chemnyco sent tremendous amounts of information ranging from photographs and blue prints to detailed descriptions of entire industrial complexes and secret processes. . . .”

5. Of particular importance for this discussion is the fact that I.G. used German military conquest to gain effective functional control of the chemical industry of the continent. In paragraph 13, we noted Georg von Scnitzler’s prediction that I.G.’s technical dominance would result in the postwar perpetuation of this control. As we will see, this control was maintained. Note the role of the N.W.7 Farben espionage organization in Bormann’s plans for the secreting of Nazi monies abroad.

Martin Bormann: Nazi in Exile; Paul Manning; Copyright 1981 [HC]; Lyle Stuart Inc.; ISBN 0-8184-0309-8; pp. 55-58.

. . . This huge organization functioned as a manufacturing and research arm of the German government, with the responsibility of discovering all possible means of increasing the military power of Germany. More than RM 4.25 billion was invested in new plants, mines, and power installations, with other millions going into new research facilities. . . . So close had Farben become to the government that I.G. always knew in advance all invasions planned by Hitler. It was to supply the materials necessary to each conquest, and when a land had been overrun and subjugated, the Farben experts would handle the consolidation and organization of the industrial facilities as additional supply sources for the German armed forces. As German troops swept across Europe and Hitler proclaimed his vision of a thousand-year Third Reich, I.G. Farben also dreamed of world empire. This was outlined with clarity in a document called Neuordnung, or ‘New Order,’ that was accompanied by a letter of transmittal to the Ministry of Economics. It declared that a new order for the chemical industry of the world should supplement Hitler’s New Order. Therefore, the document stated, Farben was fitting future industrial plans into such a framework. . . . I.G. Farben was the major chemical firm on the Continent, and as each country fell to Germany its acquisitions of chemical and dyestuff companies were enormous. I.G. also increased its investments in these by RM 7 billion. [Emphasis added.]

. . . .The close relationship of Farben to the Third Reich leadership was underscored in other ways. I.G.’s leading officials assisted in the formulation and execution of economic policies of government; its president was a member of the Reichstag; its leading scientist was a chief assistant to Hermann Goering under the Four-Year Plan; its statisticians and economists prepared intelligence for the Nazi High Command; scores of its technicians were at any given time on loan to the air and war ministries. . . . The contact men of N.W.7 throughout the world were called the I.G. Verbindungsmanner, the liaison officers between Farben back in Germany and the branches elsewhere. These I.G. Verbindungsmanner, as well as all other key Farben representatives working beyond the borders of the Third Reich, were members of the National Socialist German Workers Party. . . . So now Martin Bormann had at his command not only the Auslands-Organisation but also the I.G. Verbindungsmanner of Farben, which could be counted on to heed his orders when it was time to disperse the commercial assets of the Third Reich. . . .

6. More about how the vast international operations of the I.G. Farben firm and its various subsidiary operations was a principal element of the Bormann organization. I.G. Farben chief Hermann Schmitz discussed I.G.’s involvement with the Bormann program.

Martin Bormann: Nazi in Exile; Paul Manning; Copyright 1981 [HC]; Lyle Stuart Inc.; ISBN 0-8184-0309-8; pp. 157-158.

. . . . In testimony later given to Nuremberg investigators, Schmitz praised Bormann for the way he had directed the distribution of German assets around the world. His own Farben organization had, of course, contributed to the success of the operation. Every regional representative working for Hermann Schmitz was an exceptional businessman, or he would not have been with I.G. All had contributed sound advice in their areas of competence, the regions of the world where they represented Farben while keeping an eye on the subsidiaries of the parent concern and the 700 hidden corporations they controlled. They had provided assistance and continuing guidance in establishing the 750 new companies created on order of Bormann, who wanted more than hidden assets; Bormann wanted the money and patents and technicians put to work to create even greater assets that would bolster Germany in the postwar years. In their meeting in the chancellery, both men checked over the figures of sums disbursed, and they were accurate to the pfennig. . . .

7. As forecast by Dr. Scheid in the August 10, 1944 meeting, the corporate allies of the major German corporations, including and especially those of I.G. Farben, proved to be of great value to the uccess of the Bormann flight capital program.

Martin Bormann: Nazi in Exile; Paul Manning; Copyright 1981 [HC]; Lyle Stuart Inc.; ISBN 0-8184-0309-8; p. 156.

. . . . Powerful friends of the Bormann organization in all Western countries, including those sprinkled in control points throughout the administration in Washington and in the financial and brokerage businesses of Wall Street, the City of London, and the Paris establishment, did not wish a coordinated drive to get at these external German assets. They had understandable reasons, if you overlook morality: the financial benefits for cooperation (collaboration had become an old-hat term with the war winding down) were very enticing, depending on one’s importance and ability to be of service to the organization and the 750 corporations they were secretly manipulating, to say nothing of the known multinationals such as I.G. Farben, Thyssen A.G., and Siemens; and, as a second reason, the philosophy of free enterprise and preservation of private property. . . . (Ibid.; p. 156.)

8. Note the postwar resuscitation of I.G. Farben, in the form of the “Big Three” successor firms that grew out Farben. Although officially broken up at the end of World War II, I.G. Farben continued functioning in new form. Recent mergers (such as the 1996 merger of I.G. cartel affiliates Ciba-Geigy and Sandoz to form Novartis) indicate a new coming together of the old components of I.G. Again, pay close attention to the relationship between these companies and the Bormann capital network.

Martin Bormann: Nazi in Exile; Paul Manning; Copyright 1981 [HC]; Lyle Stuart Inc.; ISBN 0-8184-0309-8; p. 282.

. . . . By 1956, the three major multinationals (Hoechst, BASF, and Bayer) reshaped from the 159 companies within Germany that had comprised I.G. Farben were generating record profits for the original 450 major Farben stockholders, who had organized themselves into the I.G. Farben Stockholders Protective committee in Bonn. The Big Three went on expanding, tripling capitalization in 1956 from investment funds that poured in from the interlocking companies established in safe haven countries by Martin Bormann and Hermann Schmitz. There was a return, more vigorous than ever, of the huge, monolithic industrial multinationals that dominated the German economy before and during World War II. . . .

9. The enormous corporate wealth and power of the three successor firms is at the disposal of the Bormann capital network and Underground Reich.

Martin Bormann: Nazi in Exile; Paul Manning; Copyright 1981 [HC]; Lyle Stuart Inc.; ISBN 0-8184-0309-8; pp. 282-283.

. . . . Each of these three spinoffs from I.G. Farben today does more business individually than did Farben at its zenith, when its corporate structure covered 93 countries. BASF and Bayer individually boast worldwide sales of nearly $10 billion annually, while Hoechst, now the world’s largest chemical company, generated $16.01 billion in worldwide sales in 1980. Each does more business than E.I. du Pont de Nemours, with sales of $9.4 billion. The United States is, of course, the major market, one into which these German corporations continue to pour investment money for both new capital construction and corporate takeovers. Together, these three multinationals assure permanent prosperity for the original 450 Farben stockholders, their banks, and the shadowy shareholders of the Bormann organization in South America who guard and vote the Hermann Schmitz trust fund through intermediaries at the annual meetings of BASF, Bayer and Hoechst. [Emphasis added.] . . . .

10. A significant part of the I.G. Farben legacy, the Hermann Schmitz Trust is also at the disposal of the Bormann capital network and the Underground Reich.

Martin Bormann: Nazi in Exile; Paul Manning; Copyright 1981 [HC]; Lyle Stuart Inc.; ISBN 0-8184-0309-8; pp. 279-280.

. . . . If there is any doubt in Europe who, in the long run, won the peace, there is none whatsoever among the former German leaders dwelling in South America. It is a good bet that if Hermann Schmitz were alive today, he would bear witness as to who really won. Schmitz died contented, having witnessed the resurgence of I.G. Farben, albeit in altered corporate forms, a money machine that continues to generate profits for all the old I.G. shareholders and enormous international power for the German cadre directing the workings of the successor firms. . . . He was the master manipulator, the corporate and financial wizard, the magician, who could make money appear and disappear, and reappear again. His whole existence was legerdemain, played out on the gameboard of I.G. Farben and his beloved Germany. . . Their [Schmitz and Bormann] association was close and trusting over the years, and it is the considered opinion of those in their circle that the wealth possessed by Hermann Schmitz was shifted to Switzerland and South America, and placed in trust with Bormann, the legal heir to Hitler. [Hermann] Schmitz’s wealth—largely I.G. Farben bearer bonds converted to the Big Three successor firms, shares in Standard Oil of New Jersey (equal to those held by the Rockefellers), as well as shares in the 750 corporations he helped Bormann establish during the last year of World War II—has increased in all segments of the modern industrial world. The Bormann organization in South America utilizes the voting power of the Schmitz trust along with their own assets to guide the multinationals they control, as they keep steady the economic course of the Fatherland. . . .

11. The program notes the economic and political significance of the Bormann network:

Martin Bormann: Nazi in Exile; Paul Manning; Copyright 1981 [HC]; Lyle Stuart Inc.; ISBN 0-8184-0309-8; pp. 284-285.

. . . . Atop an organizational pyramid that dominates the industry of West Germany through banks, voting rights enjoyed by majority shareholders in significant cartels, and the professional input of a relatively young leadership group of lawyers, investment specialists, bankers, and industrialists, he is satisfied that he achieved his aim of helping the Fatherland back on its feet. To ensure continuity of purpose and direction, a close watch is maintained on the profit statements and management reports of corporations under its control elsewhere. This leadership group of twenty, which is in fact a board of directors, is chaired by Bormann, but power has shifted to the younger men who will carry on the initiative that grew from that historic meeting in Strasbourg on August 10, 1944. Old Heinrich Mueller, chief of security for the NSDAP in South America, is the most feared of all, having the power of life and death over those deemed not to be acting in the best interests of the organization. Some still envision a Fourth Reich. . .What will not pass is the economic influences of the Bormann organization, whose commercial directives are obeyed almost without question by the highest echelons of West German finance and industry. ‘All orders come from the shareholders in South America,’ I have been told by a spokesman for Martin Bormann. . . . .(Ibid.; pp. 284-5.)

13. Next, we review an excerpt from FTR #305, highlighting–among other things–Becker GMBH. The firm, founded by an SS veteran of the “Final Solution” with money taken from Jewish victims of the concentration camps, was absorbed into ConAgra, a major producer of foodstuffs marketed to middle, lower-middle and working-class people. The Bormann group would undoubtedly have received stock options and/or a seat on the board of directors. Thus, the Underground Reich would have direct influence in a major producer of foodstuffs for working people.

“Nazi Money Trail Heats Up after 50 Years” by Greg Steinmetz; Wall Street Journal; 4/28/97; p. A1.

14a. Next, we present an excerpt from FTR #606 about the “Aryan Gene” that provides immunity to HIV infection.

The program reviews an excerpt from testimony before a House appropriations subcommittee that was drawing up the defense budget for the following year. (The hearings were in 1969.) The testimony discusses the possibility of using genetic engineering to produce a disease that would be “refractory” to the immune system. This is virtually the clinical definition of AIDS. It is worth noting that the project was funded, and just such a disease—AIDS—appeared in just the time frame posited. It is also worth noting that, in the 2002 edition of A Higher Form of Killing, this passage is omitted!!

A Higher Form of Killing; Robert Harris and Jeremy Paxman; Hill and Wang [SC]; ISBN 0-8090-5471-X; p. 241 (p. 266 in e-book).

. . . As long ago as 1962, forty scientists were employed at the U.S. Army biological warfare laboratories on full-time genetics research. ‘Many others,’ it was said, ‘appreciate the implications of genetics for their own work.’ The implications were made more specific that genetic engineering could solve one of the major disadvantages of biological warfare, that it is limited to diseases which occur naturally somewhere in the world. ‘Within the next 5 to 10 years, it would probably be possible to make a new infective micro-organism which could differ in certain important respects from any known disease-causing organisms. Most important of these is that it might be refractory to the immunological and therapeutic processes upon which we depend to maintain our relative freedom from infectious disease.’ [Italics are Mr. Emory’s.] The possibility that such a ‘super germ’ may have been successfully produced in a laboratory somewhere in the world in the years since that assessment was made is one which should not be too readily cast aside. . . .

14b. Next, the program reviews discussion of the gene providing people of the white race [and—according to some sources—primarily those of Northern European extraction] with immunity from the AIDS virus. The program highlights that gene’s role in providing some people with immunity from the plagues that ravaged Europe centuries ago. (The gene is CCR5 delta32.)

Note that no other ethnic groups or races have the delta 32 gene that prevents infection by HIV.

 “Secrets of the Dead—Case File: Mystery of the Black Death; Background”; Secrets of the Dead.

. . . In September 1665, George Viccars, a tailor in the small, central-England village of Eyam, received a parcel of cloth ridden with plague-infected fleas from London. Four days later, Viccars died. By the end of the month, five more villagers had succumbed to the plague. The panicked town turned to their rector, William Mompesson, who persuaded them to quarantine the entire village to prevent the bacterium from spreading throughout the region. It seemed like suicide. A year later, the first outsiders ventured into Eyam, expecting a ghost town. Yet, miraculously, half the town had survived. How did so many villagers live through the most devastating disease known to man? . . .

Local Eyam lore tells befuddling stories of plague survivors who had close contact with the bacterium but never caught the disease. Elizabeth Hancock buried six children and her husband in a week, but never became ill. The village gravedigger handled hundreds of plague-ravaged corpses, but survived as well. Could these people have somehow been immune to the Black Death?”

Dr. Stephen O’Brien of the National Institutes of Health in Washington D.C. suggests they were. His work with HIV and the mutated form of the gene CCR, called ‘delta 32,’ led him to Eyam. In 1996, research showed that delta32 prevents HIV from entering human cells and infecting the body. O’Brien thought this principle could be applied to the plague bacteria, which affects the body in a similar manner. To determine whether the Eyam plague survivors may have carried delta 32, O’Brien tested the DNA of their modern-day descendents. What he found out was startling . . .”

For a disease-causing microorganism to infect the human body there must be a gateway or portal through which it enters into human cells. The plague bacterium works this way, hijacking the white blood cells sent to eliminate it. Traveling inside the white blood cells to the lymph nodes, the bacteria break out and attack the focal point of the human immune system. Dr. Stephen O’Brien felt that the mutated CCR5 gene, delta 32, may have prevented the plague from being able to enter its host’s white blood cells.

Eyam provided O’Brien an ideal opportunity to test this theory. Specifically, Eyam was an isolated population known to have survived a plague epidemic. Everyone in the town would have been exposed to the bacterium, so it’s likely that any life-saving genetic trait would have been exposed to the bacterium, so it’s likely that any life-saving genetic trait would have been possessed by each of these survivors. ‘Like a Xerox machine,’ says O’Brien, ‘their gene frequencies have been replicated for several generations without a lot of infusion from outside,’ thus providing a viable pool of survivor-descendants who would have inherited such a trait. . . .

. . . DNA samples could only be collected from direct descendents of the plague survivors. DNA is the principle component of chromosomes, which carry the genes that transmit hereditary characteristics. We inherit our DNA from our parents, thus Eyam resident Joan Plant, for instance, may have inherited the delta 32 mutation from one of her ancient relatives. Plant can trace her mother’s lineage back ten generations to the Blackwell siblings, Francis and Margaret, who both lived through the plague to the turn of the century. The next step was to harvest a DNA sample from Joan and the other descendants. DNA is found in the nuclei of cells. The amount is constant in all typical cells, regardless of the size or function of that cell. One of the easiest methods of obtaining a DNA tissue sample is to take a cheek or buccal swab. . . .

After three weeks of testing at University College in London, delta 32 had been found in 14% of the samples. This is a genetically significant percentage, yet what, really, did it mean? Could the villagers have inherited delta 32 from elsewhere, residents who had moved to the community in the 350 years since the plague? Was this really a higher percentage than anywhere else? To find out, O’Brien assembled an international team of scientists to test for the presence of delta 32 around the world. ‘Native Africans did not have delta 32 at all,’ O’Brien says, ‘and when we looked at East Asians and Indians, they were also flat zero.’ In fact the levels of delta 32 found in Eyam were only matched in regions of Europe that had been affected by the plague and in America, which was, for the most part, settled by European plague survivors and their descendants.”

Meanwhile, recent work with another disease strikingly similar to the plague, AIDS, suggests O’Brien was on the right track. HIV, the virus that causes AIDS, tricks the immune system in a similar manner as the plague bacterium, targeting and taking over white blood cells. Virologist Dr. Bill Paxton at the Aaron Diamond AIDS Research Center in New York City noticed, ‘the center had no study of people who were exposed to HIV but who had remained negative.’ He began testing the blood of high-risk, HIV-negative individuals like Steve Crohn, exposing their blood to three thousand times the amount of HIV normally needed to infect a cell. Steve’s blood never became infected. ‘We thought maybe we had infected the culture with bacteria or whatever,’ says Paxton. ‘So we went back to Steve. But it was the same result. We went back again and again. Same result.’ Paxton began studying Crohn’s DNA, and concluded there was some sort of blocking mechanism preventing the virus from binding to his cells. Further research showed that that mechanism was delta 32. Scientists studying HIV first learned about the gateway-blocking capacity of the CCR5 mutation in 1996. Several drug companies, then, quickly began exploring the possibility of developing pharmaceuticals that would mimic delta 32 by binding to CCR5 and blocking the attachment of HIV. . . .

14c. In June of 2009, it emerged that CCR5 delta-32 was used in transplant therapy administered by a German doctor to an HIV-positive leukemia patient. It appears that the patient was cured of HIV! The German doctor deliberately selected a CCR5 delta-32 positive donor for the stem cells used for the transplant. Dr. Gupta, quoted in the following article, wonders why more publicity wasn’t afforded this event. Why indeed?

“Local Physician:HIV/AIDS Cure Getting Little Publicity” by Bob Morgan; Gulf Coast News Today; 5/27/2009.

A Foley [Alabama] physician said what appears to be the first case of HIV/AIDS cure in the world is getting little mention in the media.

Dr. Awadhesh K. Gupta, medical director at Foley Walk-In Med Care, said he first heard of the medical breakthrough in April when he attended the Annual Conference of the American College of Physicians in Internal Medicine in Philadelphia.

It’s a conference Gupta tries to attend every year.

“This is the most prestigious organization of physicians in Internal Medicine and is responsible for certifying post graduate training in Internal Medicine. It is also one of the oldest,” he said.

According to Gupta, who has been practicing medicine in the South Baldwin area since 1997, the cure was first reported in early 2008 by a group of physicians from Germany at the annual conference on “Retroviruses and Opportunistic Infections” in Boston. The New England Journal of Medicine, one of the most prestigious medical journals in the world, finally published the report in its Feb. 12, 2009, issue, Gupta said.

So why has the news of the first case of HIV/AIDS cure received so little attention where the public is concerned?

“I can’t be sure as to why so little publicity,” Gupta said recently.

“My guess is that most scientific researchers are somewhat stunned that a clinician — not a research scientist — has been able to come up with the cure. Most of the big research money and big name American institutions are somewhat embarrassed to acknowledge that the very first case of HIV cure is not coming from their institutions.”

The cure, instead, is coming from Charity University Hospital in Berlin, Germany, and the doctor is Gero Huetter, who works in the Department of Hematology, Oncology and Transfusion Medicine at the same hospital.

Asked about the reaction of attendees at the medical conference in Philadelphia as regarded the news of an HIV/AIDS cure, Gupta said, “Unfortunately, because of the hectic schedule, I did not try to engage too many physicians. However, the doctor presenting this information seemed extremely excited about it.”

As Gupta explains the case and cure in question, a 40-year-old American working in Berlin had been HIV-positive for 10 years. The patient’s HIV infection had been under control for four years with “conventional HAART treatment regimen” (Highly Active Anti-Retroviral Therapy).

When the patient developed leukemia, however, a bone marrow transplant of stem cells was done using standard protocol, which Gupta said includes radiation therapy and chemotherapy prior to the transplant.

“Remember, once you stop HIV drugs, the HIV viral count rises very rapidly, usually within a few days to a week,” Gupta said.

According to Gupta, Huetter, the German physician treating the American, deliberately chose a stem cell donor who had a gene mutation known as “CCR-5 Delta- 32,” rather than using the best matched donor.

Gupta said Huetter remembered research first observed in 1996 – research Gupta said is well known in the scientific community. That research found that certain gay men in the San Francisco area remained uninfected with HIV in spite of engaging in risky sexual activities. As it was later discovered, those men had the CCR-5 Delta-32 gene mutation.

As it turned out, the patient’s stem cell transplant was a success, Gupta said, even though the patient had to have a second stem cell transplant (from the same donor) when his leukemia relapsed.

“This patient has been off all his HIV drugs for two years now,” Gupta said. “He continues to show no detectable signs of HIV in all the known places HIV is detected — no signs of HIV in his blood, bone marrow, lymph nodes, intestines or brain.” Also, the patient’s T-cell count remains normal.

Thus, according to Gupta, within the limits of scientists’ ability to detect HIV, it appears this patient’s HIV has been “eradicated.”. . .

14d. The devastating implications of the findings discussed above were eloquently presented in an online editorial:

“Aryan Genes Immune to Death from AIDS” by geminiwalker_ink. (This post appears to have disappeared from the internet)

This is the nightmare of AIDS no one wants to believe. As we come closer to celebrating, on December 1, yet another World AIDS Day, let’s take a good hard look at what’s really going on before we pour more of our ever diminishing hard earned money down yet another horrendous sinkhole. It has been found that some Caucasians who have tested positive for the HIV virus were found to take a very long time to actually develop ‘full-blown’ AIDS (as they call it). It has since been discovered (since 1997) that 20% of European Caucasians have the so-called ‘Aryan’ genetic disposition. If both your parents, in other words, are of Aryan descent, it appears you can never die of AIDS even though you might be infected.

The reason for this is in the genetic coding of the killer T-cells, which are part of the body’s immune system protective shield. These are the cells that are attacked by the HIV retrovirus. The location of the attack has been discovered. It is on the CCR5 gene in the 3rd DNA gene pair. The particular location is the Delta 32 RECEPTOR SITE. If either of your DNA pairs (from either your mother or your father) is DELTA 32 POSITIVE then the HIV virus can attach itself at that point. If you are DELTA 32 NEGATIVE then HIV just floats around in your blood harmlessly for you.

But even though you may be DELTA 32 NEGATIVE at both sites, you can supposedly still spread the virus. What has been discovered is that these 20% of European Caucasians are members of the Aryan gene pool. Also it has been discovered that the farther north you go in Europe, say in Norway, Finland, Sweden, etc., you find the highest percentage of people that are DELTA 32 NEGATIVE at the CCR5 gene allele.

That this would be a simple coincidence is beyond all human reason. To say that HIV suddenly crawled out of the woodwork in Central Africa by someone being bitten by a green tree monkey is one thing. But then to say that the only human gene pool on Earth that is immune to HIV is the Aryan Race is a coincidence that even Howdy Doody wouldn’t buy. . . .

15a. Looking ahead to what figures to be a very, very dark future, we feel compelled to revisit some key aspects of the AIDS epidemic, in light of the alarming proliferation of genetically-modified organisms. Humanity has failed badly in its approach to the disease, ignoring the evidence that it was deliberately created.

In FTR #606, we encapsulated information about AIDS collated over more than a quarter of a century, dovetailing that with indications that the boiler-plate research on the disease may track back to the Third Reich and its minions hired by the U.S. under Project Paperclip. We supplemented this in FTR #682.

In that program, we made a number of key points that should be revisited in the context of genetically-modified organisms and their rapid proliferation:

  • The prospect of using genetic engineering to create a disease that would be resistant to and/or attack the human immune system was forecast in House Appropriations hearings for the defense budget for fiscal year 1970: “. . . As long ago as 1962, forty sci­en­tists were employed at the U.S. Army bio­log­i­cal war­fare lab­o­ra­to­ries on full-time genet­ics research. ‘Many oth­ers,’ it was said, ‘appre­ci­ate the impli­ca­tions of genet­ics for their own work.’  The impli­ca­tions were made more spe­cific that genetic engi­neer­ing could solve one of the major dis­ad­van­tages of bio­log­i­cal war­fare, that it is lim­ited to dis­eases which occur nat­u­rally some­where in the world. ‘Within the next 5 to 10 years, it would prob­a­bly be pos­si­ble to make a new infec­tive micro-organism which could dif­fer in cer­tain impor­tant respects from any known disease-causing organ­isms. Most impor­tant of these is that it might be refrac­tory to the immuno­log­i­cal and ther­a­peu­tic processes upon which we depend to main­tain our rel­a­tive free­dom from infec­tious dis­ease.’ The pos­si­bil­ity that such a ‘super germ’ may have been suc­cess­fully pro­duced in a lab­o­ra­tory some­where in the world in the years since that assess­ment was made is one which should not be too read­ily cast aside. . .”
  • There is a hereditary immunity to HIV infection that is present only in the white race and only in pure-bred northern Europeans (“Aryans”)
  • There is another hereditary trait that predisposes people of African extraction to HIV infection.
  • At the end of World War II, the U.S. implemented Project Paperclip, under which Nazi scientists (many of them war criminals of the first order) were brought into the country and put to work at the heart of the U.S. defense establishment: “Near­ing the end of World War II, the United States and the Soviet Union raced to recruit Ger­man sci­en­tists for post­war pur­poses. Under a top-secret pro­gram code-named Project PAPERCLIP, the U.S. mil­i­tary pur­sued Nazi sci­en­tific tal­ent ‘like for­bid­den fruit,’ bring­ing them to Amer­ica under employ­ment con­tracts and offer­ing them full U.S. cit­i­zen­ship. The recruits were sup­posed to be nom­i­nal par­tic­i­pants in Nazi activ­i­ties. But the zeal­ous mil­i­tary recruited more than two thou­sand sci­en­tists, many of whom had dark Nazi party pasts. . . .” (Lab 257 by Michael Carroll; p. 7.)
  • One of the Nazi researchers imported into the U.S. was Dr. Erich Traub.  According to Michael C. Carroll, author of Lab 257: The Disturbing Story of the Government’s Secret Plum Island Germ Laboratory, Traub was a key administrator of the Third Reich’s biological warfare research program and reported directly to SS chief Heinrich Himmler. ” . . . . Every­body seemed will­ing to for­get about Erich Traub’s dirty past—that he played a cru­cial role in the Nazis’ ‘Can­cer Research Pro­gram,’ the cover name for their bio­log­i­cal war­fare pro­gram, and that he worked directly under SS Reichs­fuhrer Hein­rich Himm­ler. They seemed will­ing to over­look that Traub in the 1930’s faith­fully attended Camp Sigfried. In fact, the USDA liked him so much, it glossed over his dubi­ous past and offered him the top sci­en­tist job at the new Plum Island Laboratory—not once, but twice. Just months after the 1952 pub­lic hear­ings on select­ing Plum Island, Doc Sha­han dialed Dr. Traub at the naval lab­o­ra­tory to dis­cuss plans for estab­lish­ing the germ lab­o­ra­tory and a posi­tion on Plum Island. . . .” (Lab 257 by Michael Carroll; p. 10.) NB: Traub was never formally inducted into the SS, but reported directly to Heinrich Himmler. He was Plum Island’s top scientist, not its founder.
  • The Nazis began research­ing toxic agents on apes and then moved on to humans—inmates in con­cen­tra­tion camps. AIDS results from a mon­key virus that even­tu­ally jumped to humans as well. Does the pro­gres­sion in the Nazi death camps of test­ing on apes to test­ing on humans have any rela­tion­ship with the pro­gres­sion of a simian virus to infec­tion of humans? Might the cre­ation of AIDS have stemmed from Nazi research? Is it an acci­dent that the hered­i­tary immu­nity from HIV infec­tion is only present in the white race, and [accord­ing to some sources] North­ern Euro­peans in par­tic­u­lar? Is it an acci­dent that peo­ple of African extrac­tion are par­tic­u­larly sus­cep­ti­ble to HIV infec­tion?
  • Dr. Franz Liesau Zaccharias was the Abwehr agent who obtained the apes for the Nazi medical experiments. He was badly wanted by Western intelligence after the warWhy?! Western intelligence agencies certainly didn’t need anyone to teach them how to obtain apes from Africa. Experimenting on animals is not a war crime. The suspicion here is that he had discovered something of value during his primate work. Evidence also suggests that he remained part of The Underground Reich.
  • Among the dis­eases that Liesau Zacharias’ ani­mals were used for test­ing was “the plague”! Did the Nazis note that some peo­ple appeared to be immune to infec­tion with plague? Were tis­sue and/or sera sam­ples taken and pre­served for fur­ther study? Was this in any way con­nected to the even­tual evo­lu­tion of the CCR5-delta 32 gene as a hered­i­tary pro­tec­tion against infec­tion by HIV? Is it pos­si­ble that Liesau Zacharias was actu­ally tar­geted for recruit­ment by the U.S. for Project Paper­clip? Did Liesau Zacharias expe­ri­ence an out­break of immun­od­e­fi­ciency among his pri­mates await­ing ship­ment to Ger­many? Might such an out­break have been due to SIV? Did Liesau Zacharias take tis­sue and sera sam­ples from infected pri­mates? Might such a devel­op­ment have been related to his impor­tance to the Allies?
  • Kaiser Permanente has discussed the dangers of GMO’s in a newsletter, linking them to “devastating” threats to human health.
  • We should not fail to recognize the danger of using GMO’s in food, water, medicine or other “vectors” to achieve the goals of Nazi genocide.
  • In FTR #305, we discussed the absorption of Becker GMBH into ConAgra foods, a major player in the food industry. Becker was begun by an SS officer with funds from Holocaust victims. How many other major food firms are Underground Reich properties? Might they slowly destroy their “racial enemies” by using food as a vector for “pro-Aryan” GMO’s?
  • In that context, we are very suspicious of Jorge Paulo Lemann and 3G Capital, a major player in the food and brewing industries. They own Anheuser-Busch (the largest American brewer), Heinz foods, the company that supplies McDonald’s, Burger King and many other firms. Lemann is a Brazilian-born, Swiss-based “self-made man.” His  profile and that of his business interests fit the profile of a Bormann firm to a tee. Keep on eye on this.
  •  Lemann’s “new” Anheuser-Busch is facing class-action litigation for watering its beer! What else are they doing to the food and beverages that they manufacture?
  • In time, as well, the health crises that will stem from the indiscriminate use of GMO’s, lax environmental regulation become manifest, the increase in health care costs will place additional (perhaps catastrophic) strain on the U.S. budget. The calls for austerity will surely multiply and become more shrill in this event.

 “Top US Healthcare Giant: GMOs Are Devastating Health” by Anthony Gucciardi [NaturalSociety]; Reader Supported News; 11/28/2012.

Just days after a leading genetically modified organism (GMO) researcher spoke out against GMOs and how many pro-GMO ‘scientists’ are in bed with Monsanto or carry their own GMO patents, the largest managed healthcare provider in the United States is now publicly speaking out against GMOs. In a recent newsletter, the Kaiser Permanente company discussed the numerous dangers of GMOs in a recent newsletter and how to avoid them.

Explaining how GM ingredients have been linked to tumors and organ damage in rats in the only lifelong rat study available, the newsletter highlighted how the only real long- term research indicates that GMOs are a serious health danger. The newsletter, which you can view here, states:

“Despite what the biotech industry might say, there is little research on the long-term effects of GMOs on human health. Independent research has found several varieties of GMO corn caused organ damage in rats. Other studies have found that GMOs may lead to an inability in animals to reproduce.” . . . .

15b. An overview of Jorge Paulo Lemann’s business undertakings, noting as we go his Germanic last name and the profound Bormann presence in Latin America and Switzerland (Lemann’s place of residence):

“Jorge Paulo Lemann”; Forbes; 5/27/2016.

Jorge Paulo Lemann is Brazil’s richest man thanks to his stake in Anheuser-Busch InBev, the world’s largest brewer, which he owns through private equity firm 3G Capital together with fellow billionaires and longtime partners Carlos Sicupira and Marcel Herrmann Telles [a nice Iberian name, no?–D.E.]. The trio also has stakes in Restaurant Brands International, which owns Burger King and Tim Hortons and is listed both the New York and Toronto stock exchanges. In 2013 Lemann’s private equity firm bought H.J. Heinz & Company for $23 billion together with Warren Buffett’s Berkshire Hathaway. It was 3G Capital’s second acquisition of an American name brand. In 2010, 3G Capital bought Burger King in a leveraged buyout.

 

Discussion

3 comments for “FTR #912 Food for Thought”

  1. The Aids virurs reserachers who were developing a vaccine for AIDS were killed on MH17. Such a discovery financially hurt pharmaceutical companies that make drugs cocktails and antibiotics, etc., used to treat HIV and diseases of its victims such as the pneumonia.

    AIDS treatments cost the US a fortune in hospitalizations, medical treatments, and pharmaceutical drugs.

    http://www.independent.co.uk/news/world/europe/malaysia-airlines-crash-joep-lange-among-up-to-100-aids-researchers-and-activists-on-board-flight-9613821.html

    Malaysia Airlines flight MH17 crash: Was the cure for Aids lost along with Joep Lange and 100 top researchers?
    By Lizzie Dearden @lizziedearden
    Independent UK Friday 18 July 2014

    There are fears the cure for Aids could have been lost with 100 of the “best and brightest” scientists and researchers on board Malaysia Airlines flight MH17.

    Joep Lange, a world-renowned researcher and former president of the International Aids Society, was with the group heading to the global Aids 2014 conference in Melbourne, Australia.

    The exact number of scientists he was travelling with has not been confirmed but delegates in Sydney were told that emails indicted around 100 attendees were on the ill-fated plane.

    Nine British passengers, including a student, former BBC journalist and two Newcastle United fans, were among the 298 people killed when the Boeing 777-200 was reportedly shot down as it passed over the war-torn country on Thursday.

    Trevor Stratton, a Canadian HIV researcher attending the conference told ABC researchers had been getting close to a vaccine against Aids.

    “What if the cure for AIDS was on that plane? Really? We don’t know,” he said. “There were some really prominent researchers that have been doing this for a very long time and we’re getting close to vaccines and people are talking about cures and the end of AIDS. “And you can’t help but wonder what kind of expertise was on that plane.” Professor Richard Boyd, director of the Monash Immunology and Stem Cell Laboratories, told Guardian Australia there were “some serious HIV leaders” on board.

    “This will have ramifications globally because whenever you lose a leader in any field, it has an impact. That knowledge is irreplaceable,” he said. “We’ve lost global leaders and also some bright young people who were coming through. It’s a gut-wrenching loss. I was involved in the aftermath of 9/11 in New York and it brings back that level of catastrophe.”

    Clive Aspin, a HIV researcher in Australia ahead of the Aids conference said there was a “huge feeling of sadness” among delegates, with people crying in corridors. He added: “These people were the best and the brightest, the ones who had dedicated their whole careers to fighting this terrible virus.”

    News of Mr Lange’s death sent ripples through the Aids community, who paid tribute to a “giant” in the field who made invaluable advances in affordable treatment for sufferers in Asia and Africa.
    Scientists at the Kirby Institute at the University of New South Wales (UNSW) in Australia said Mr Lange was travelling with his wife, Jacqueline. Director of the institute, Professor David Cooper, said his friend had an “absolute commitment” to HIV treatment and care in Asia and Africa. He added: “The joy in collaborating with Joep was that he would always bring a fresh view, a unique take on things, and he never accepted that something was impossible to achieve. Our joint work in Bangkok, the HIVNAT centre, will stand as his legacy.”

    Professors Cooper had worked with Mr Lange on HIV treatment for decades and concentrated on “resource-poor” areas from the mid-1990s, attempting to prevent the disease taking hold in Asia the way it had in Africa. In 1996 they established a research centre in Bangkok called HIV-NAT with a Thai colleague.

    According to UNSW, Mr Lange had worked in Aids research and treatment since 1983 and made “ground-breaking” contributions to the development of affordable treatments. He also played a pioneering role in exploring affordable and simple antiretroviral drug regimens for the prevention of mother-to-child transmission.

    At the time of his death, Professor Lange was Professor of Medicine at the Academic Medical Center, University of Amsterdam and Senior Scientific Advisor to the International Antiviral Therapy Evaluation Centre, Amsterdam. He was co-director of the HIV Netherlands Australia Research Collaboration (HIV-NAT) and a former president of International AIDS Society.

    The group expressed its “sincere sadness” at news of the deaths of colleagues and friends on MH17, confirming they were on route to attend the 20th International AIDS Conference starting in Melbourne on Sunday. “At this incredibly sad and sensitive time the IAS stands with our international family and sends condolences to the loved ones of those who have been lost to this tragedy,” a statement said.
    “The IAS has also heard reports that among the passengers was a former IAS President Joep Lange and if that is the case then the HIV/AIDS movement has truly lost a giant.”

    In 2001, he founded and chaired the PharmAccess Foundation, a not-for-profit organisation based in Amsterdam, designed to improve access to therapy in developing countries and was a founding editor of the academic journal, Antiviral Therapy.

    Glenn Thomas, a British media relations co-ordinator for the World Health Organisation, was also part of the delegation, according to WHO officials. The 49-year-old was a former BBC journalist from Blackpool and had recently celebrated his birthday, according to The Times.

    Nine Britons, 154 Dutch, 27 Australians, 38 Malaysians, 23 US citizens and 80 children were among those on board Boeing 777-200 from Amsterdam to Kuala Lumpur.

    None of the 298 and crew survived the crash, near the town of Grabovo in eastern Ukraine, which has seen fierce fighting between separatist militias and government troops.

    Both pro-Russian rebels and the Ukrainian government denied shooting the aircraft down after US authorities said intelligence analysis showed it had been hit by a surface-to-air missile.

    Posted by Chem | July 1, 2016, 6:04 pm
  2. 2009 New England Journal of Medicine Article on CCR5 Delta 32/Delta 32 Gene Therapy for long term control of HIV-1

    http://www.nejm.org/doi/full/10.1056/NEJMoa0802905#t=article

    Pretty much the same info Dave covered in the program in the Gulf Coast News Today article but from the highly respected medical journal rather than the popular press. Which is a very good sign the info is legitimate and not made up.

    Posted by GK | July 2, 2016, 7:04 pm
  3. Bayer (a former division of IG Farben) is trying to buy Monsanto with CASH that few companies have the money to finance. Bayer wants to become dominant in the farm supplies industry, combining its crop science business with Monsanto’s strength in seeds in a form of vertical integration. This is part of an old Nazi strategy to develop dominant cartels on the world stage with the Underground Reich companies.

    http://mobile.reuters.com/article/idUSKCN11B2G9

    Reuters Tue Sep 6, 2016 | 10:09 AM EDT
    Bayer sweetens Monsanto bid as talks enter final stretch

    By Ludwig Burger, Arno Schuetze and Greg Roumeliotis | FRANKFURT/NEW YORK

    (Reuters) – German pharmaceutical and crop chemicals manufacturer Bayer AG says talks with Monsanto Co have advanced and it is now willing to offer more than $65 billion, a 2 percent increase on its previous offer for the world’s largest seeds company.

    “Both sides are gradually nearing consensus,” one person familiar with the matter said.

    Monsanto has also agreed to open its books for Bayer to conduct due diligence checks on the company’s business, two sources close to the matter said.

    Bayer’s previous offer was already the largest all-cash takeover bid on record with a deal with Monsanto aimed at giving the German company a shot at grabbing the top spot in the fast-consolidating farm supplies industry, combining its crop science business with Monsanto’s strength in seeds.

    Bayer now says it is prepared to offer $127.50 per share in a negotiated deal, up from its previous offer of $125 per share.

    But German daily newspaper Rheinische Post also reported late on Monday that an offer of $130 per share may be necessary to get a deal with Monsanto “in a swift and friendly way.”

    Bayer was still considering all options regarding Monsanto, including striking a friendly deal, making a hostile bid or pulling its offer, a person familiar with the matter told Reuters.

    Bayer’s shares were down 0.25 percent at 94 euros by 0934 GMT on Tuesday. Monsanto’s shares last traded at $107.44 and analysts at brokerage Equinet said Bayer has now effectively capped its Monsanto bid.

    “We infer from Bayer’s statement that failure to agree a deal at $127.50/share could imply a risk to Monsanto shareholders of either a hostile bid at a lesser consideration, or no deal at all,” they said in a note.

    Analysts from Baader Helvea disagreed. “We still expect a bid per share in the $130-135 range before Monsanto comes to the table. As such, we continue see the Bayer shares remaining under pressure as the negotiations continue,” they said in a note.

    In a brief statement, Monsanto said on Monday it had been engaged in “constructive” negotiations with Bayer, during which it received the updated non-binding proposal of $127.50 per share in cash.

    The Saint Louis-based company added that it was continuing these conversations as it evaluated Bayer’s offer, as well as proposals from other parties it did not name. It cautioned that there was no certainty that any deal would occur.

    Some Bayer shareholders, however, continue to criticize the proposed merger, saying it would increase Bayer’s exposure to agriculture at the expense of its pharmaceutical business.

    “We knew that Bayer would have to bid higher and this offer is probably getting closer to succeeding, but it doesn’t change our view that it presents significant risks to shareholders,” said Greg Herbert, co-manager of the Jupiter Global Equity Income Fund.

    “The company will be left with a highly geared balance sheet and the management effort to integrate the two businesses could easily lead to the larger pharmaceutical business being neglected.”

    John Bennett of fund manager Henderson said that he opposed the revised offer.

    “Bayer have backed themselves into a corner,” he said in emailed comments. “The money would have been better spent buying their own stock. Alas, for shareholders, it was not to be.”

    Posted by Anonymous | September 6, 2016, 6:12 pm

Post a comment